Drug Department Recalls Substandard Linares M 850 Tablets Manufactured by Grace Pharmaceuticals

29th June 2026, Kathmandu

Department of Drug Administration has directed the immediate suspension of the sale and distribution of Linares M 850 Tablets manufactured by Grace Pharmaceuticals Pvt Ltd after laboratory testing confirmed that the product failed to meet prescribed quality standards.

Drug Department Recalls Substandard

The regulatory intervention emphasizes the rigorous oversight maintained by health authorities to protect public wellness, prevent the circulation of compromised therapeutic agents, and hold manufacturing firms accountable to regional chemical benchmarks.

Enforcing high safety standards is especially vital for metabolic treatments designed for conditions like Type 2 diabetes. Inconsistent dosing or chemical impurities in anti-diabetic formulations can lead to severe health fluctuations for users who rely on daily pill regimens to balance their blood glucose ranges. By executing rapid market recalls, the national drug controller acts as a major line of defense against sub-therapeutic commercial products entering rural or urban healthcare channels.

Detailed Laboratory Verification of the Affected Anti Diabetic Batch

According to the department, samples collected during routine market surveillance were tested at the National Medicines Laboratory, where Batch No. TLMS-006 was found to be substandard. Routine random tracking operations are performed regularly by field inspectors who pull random items from regional pharmaceutical distributors, large institutional hospital supply rooms, and public pharmacies across various municipal zones.

Once the gathered components reached the central testing facility, analysts identified that this specific batch deviated from required pharmaceutical specifications. Following the definitive presentation of the laboratory test results, the DDA ordered the manufacturer to immediately recall the affected batch from the market. This regulatory measure ensures that any remaining units are blocked from purchase before they can cause adverse clinical reactions or treatment failure.

Advertisement

Direct Statutory Framework Invoked for Immediate Product Removal

The current administrative enforcement relies on deep legal mandates designed to maintain complete healthcare compliance within the national territory. The recall has been issued under Section 14 of the Drugs Act, 1978 (2035 B.S.), requiring the company to stop selling and distributing the specified batch without delay. This specific federal act gives extensive authorization to state regulators to penalize manufacturing entities that violate national health criteria.

The statutory guidelines demand that the domestic producer establish immediate contact with its independent regional sales networks to freeze the transit of all related containers. Grace Pharmaceuticals Pvt Ltd must collect every available item from this designated production cycle, catalog the exact volume of recovered boxes, and present a transparent reconciliation report directly to the central regulatory office to confirm full compliance with the state mandate.

Strict Official Warnings Issued to Healthcare Providers and the Public

To ensure that the dangerous components are removed from daily clinical use, the state agency has distributed clear warnings across multiple media channels. The department has also urged pharmaceutical distributors, healthcare institutions, pharmacies, and the general public not to sell or use the affected batch and to exercise caution. This wide public notification helps cover remote communities where individual small shops might overlook standard internal recall circulars.

Medical professionals and pharmacists have been instructed to cross check their current inventory records against Batch No. TLMS-006 immediately. Any matched containers should be separated from active stock, labeled as defective, and returned through official commercial supply loops. Consumers who currently use this specific medication are advised to check their personal pill boxes and consult with their primary physicians to secure safe alternative batches or substitute brands.

For More: Drug Department Recalls Substandard